In This Webinar...
The drug development world certainly felt the immediate impact of the COVID-19 pandemic. But we are only just beginning to think about the long-term impacts of how the policies, practices and principles that we relied on during 2020 will continue to shape clinical research and drug development practices for years to come. In addition to the operations challenges, COVID-19 also brought us new ethical challenges, which will also continue to resonate through the future of the drug development community.
- Scientific communication by pre-print and press release;
- Empowering patient advocacy groups who have seen the potential speed of making new therapies available to patients
- Long-term impacts on clinical trial design considerations
- Informed consent in emergency settings and for unapproved products under EUA
- Human challenge studies
|Arthur L. Caplan, Drs. William F. and Virginia Connolly Mitty Professor of Bioethics
NYU School of Medicine
Director, Division of Medical Ethics